Is retatrutide legal in the US?

What retatrutide is

Retatrutide is a once-weekly injection being developed for obesity. It's a single molecule that activates three hormone receptors: GIP, GLP-1, and glucagon. That's why it's often called a “triple agonist.” Semaglutide targets one of those receptors and tirzepatide targets two.

Lilly is testing it in a Phase 3 program called TRIUMPH. On July 23, 2026, the company reported positive results from two more of those trials and said retatrutide had now succeeded in five Phase 3 studies. It also said it would submit its application to the FDA in the first quarter of 2027, after finishing the manufacturing and quality-control data regulators require.

Why it can't be compounded

Compounding pharmacies can only work from bulk ingredients that qualify under federal law. In a letter to pharmacies, the FDA explained that retatrutide doesn't qualify on any count:

• It isn't the subject of an official USP or NF monograph.
• It isn't a component of any FDA-approved drug.
• It isn't on the 503A bulks list, the 503B bulks list, or the FDA's drug shortage list.

The FDA's guidance on unapproved GLP-1s states plainly that retatrutide can't be used in compounding under federal law. So a clinic or pharmacy offering “compounded retatrutide” isn't operating under any legal exemption.

What about retatrutide sold online?

Anything sold online as retatrutide comes from an unregulated source. The FDA has issued warning letters to telehealth companies marketing it, including directly to consumers, and to ingredient distributors selling it to compounders. It has also warned sellers that label it “for research purposes” or “not for human consumption.” Lilly has filed its own lawsuits against companies it says are selling unapproved retatrutide.

Lilly's own announcements describe retatrutide as an investigational molecule that can't legally be sold or marketed for human use. Why a “research use only” label doesn't change that →

When could retatrutide be approved?

Lilly plans to file in the first quarter of 2027. The FDA's review of a new drug application commonly takes about a year from submission, and it can be shorter with priority review. Either way, a decision before late 2027 is unlikely, and approval isn't guaranteed.

Approval also wouldn't open the door to compounding. Once a drug is approved and commercially available, pharmacies generally can't regularly make copies of it, which is the same rule now applied to semaglutide and tirzepatide. How that works →

How to get retatrutide legitimately: clinical trials

A clinical trial is the one legal route today. Legitimate trials are registered on ClinicalTrials.gov, list the sponsor and the study sites, and screen people before enrolling them. Trials enroll specific groups, so whether you qualify depends on the study.

If you're not in a trial, the approved options are the legal ones: semaglutide, tirzepatide, and the other FDA-approved GLP-1s, prescribed by a licensed clinician. How to vet a provider →